MonoGen Inc. Submits 180-Day PMA Supplement for New Manufacturing Facility
CHICAGO, ILLINOIS--(Marketwire - October 22, 2007) - MonoGen, Inc. ("Corporation") (TSX: MOG) today announced that it has submitted a 180-Day PMA Supplement seeking FDA approval to manufacture the MonoPrep Pap Test at its new manufacturing facility located in Waukegan, Illinois. MonoGen expects that the FDA will complete review and action on this supplement within 180 days.